FDA Points To Premarket Clearance For Direct-To-Consumer Genetic Tests
This article was originally published in The Tan Sheet
Executive Summary
FDA tells direct-to-consumer genetic testing company 23andMe that it should immediately stop marketing its Personal Genome Service in a strongly worded, lengthy warning letter that experts say could provide guidance across the sector. The firm says it will address the agency’s concerns.